Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival
Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival
复制标题
DOI：
10.1200/jco.2003.03.052
复制
发表时间：
2003-09-01
影响因子：
45.3
通讯作者：
Buchholz, TA
中科院分区：
文献类型：
--
作者：
Woodward, WA;Strom, EA;Buchholz, TA
目的：为了评估如何实施2003年美国癌症联合委员会（AJCC）分期系统将影响乳腺癌patients.Patients和方法的特定阶段的生存：1,350例患者接受治疗的连续机构协议与乳房切除术和辅助阿霉素为基础的化疗记录进行了审查。根据1988年和2003年AJCC分期标准进行回顾性病理分期。采用Kaplan-Meier法计算总的分期特异性生存期（OS），并通过log-rank检验比较假设差异。结果：1,087例11期患者中有605例根据1988年分类系统进行分期，根据2003年分类系统进行分期。使用2003年系统，11期疾病患者的10年OS显著改善（76% [2603] vs65%[1988]; P
Purpose : To evaluate how implementation of the 2003 American Joint Committee on Cancer (AJCC) staging system will affect stage-specific survival of breast cancer patients.Patients and Methods: Records of 1,350 patients treated on sequential institutional protocols with mastectomy and adjuvant doxorubicin-based chemotherapy were reviewed. Pathologic stage was assigned retrospectively according to the 1988 and the 2003 AJCC staging criteria. Overall stage-specific survival (OS) was calculated using the Kaplan-Meier method, and hypothetical differences were compared by the log-rank test.Results: Six hundred five of 1,087 patients with stage 11 disease according to the 1988 classification system had stage 11 disease according to the 2003 system.. The 10-year OS for patients with stage 11 disease was significantly improved using the 2003 system (76% [2603] v 65% [1988]; P